Vicor Corporation

Executive Summary

SELL, Low conviction. Rated SELL, Low conviction. The business is improving fast, with management now guiding to over $600 million of 2026 revenue, rising gross margin, and strong advanced-product demand, but the stock still trades at 83.71x earnings and 25.88x sales versus peers at 29.7x P/E and 2.5x P/S. That leaves little room for any slip in licensing revenue timing, capacity expansion, or the late-2027 production ramp implied by second-generation VPD programs.

Investment Thesis

Vicor is no longer a story stock without numbers behind it. The numbers are now real. Management guided to over $600 million of 2026 revenue, Q2 revenue reached $143.4 million, advanced products rose to $94.2 million, and gross margin improved to 58%. That is a meaningful improvement from the 2024 period, when the company withheld quarterly guidance, book-to-bill was below 1, and Gen 5 timing was still uncertain. The business is clearly moving in the right direction.

The problem is that the stock already prices in a lot more than execution of the 2026 plan. At $268.34, VICR trades at 83.71x P/E and 25.88x P/S on a $12.2 billion market cap, despite FY2025 operating margin of only 5.1% and FCF reported at $0.0B. That is venture-style valuation for a company that still needs a second fab to support its long-term $2.5 billion ambition and has acknowledged the first fab is nearing utilization. Investors are paying today for capacity, margin, and customer-conversion outcomes that still sit in the future.

The case now depends on three things. First, AI-linked power programs need to keep scaling beyond the current licensing help. Q2 included $15 million of license revenue, Q3 falls to $5 million, then the following four quarters are expected at $10 million each, so the earnings cadence will not be smooth. Second, the second-generation VPD engagements with hyperscalers and OEMs must convert into production ramps in late Q3 to Q4 2027, not slip again. Third, manufacturing expansion has to stay ahead of demand enough that the company can choose customers selectively without capping growth.

This is why conviction is low rather than high. The fundamentals are improving quickly, but the setup is awkward after a 45.86% 1-week surge and with shares 28.6% above the 200-day average. A great business trajectory can still be a bad stock entry when the market pre-pays for too much of it. Until earnings power catches up to the valuation, avoiding the stock remains the cleaner call.

Key Metrics

Financial Strength

Financial risk is low. Vicor carries effectively no leverage, with Debt/Equity 0.01 and Debt/EBITDA 0.07, and the 13.25 current ratio gives ample near-term liquidity. The more important question is not solvency but conversion of growth into durable cash flow, because reported FY2025 FCF was $0.0B and the company still needs significant capacity investment to support the next leg of scale. Margin direction is encouraging, especially the move to 58% gross margin in Q2 2026, but that level still benefits from licensing and favorable mix, so the market needs proof that product margins can stay elevated as capacity expands.

Competitive Position

Vicor's edge is power density and efficiency in demanding applications where board space, thermals, and performance matter enough to justify custom adoption. That matters most in AI infrastructure, HPC, aerospace and defense, and industrial systems, where design wins can persist once qualified. The moat is real but not impregnable, because durability over the next 3 to 5 years depends on scaling manufacturing and turning current hyperscaler engagement into repeat production rather than one-off engineering wins.

Management & Guidance

Management's current guide is clear and materially more confident than it was in late 2024. CFO Jim Schmidt said, "As we bring on incremental capacity, we expect a nearly 10% increase in Q3 revenue and over $600 million in 2026 revenue," and also said, "In view of its accounting treatment, this license agreement is expected to contribute $5 million in Q3 and $10 million per quarter for the following four quarters." That guidance looks more credible than past commentary because it is supported by 26% sequential backlog growth, book-to-bill above 1, and a string of large EPS beats. The caution is that timing has slipped before, especially around Gen 5 and production ramps, so investors should trust the demand signal more than the exact quarter-by-quarter cadence.

Segment Analysis

• Advanced products (Q2 2026 revenue $94.2M): Up 45% sequentially, driven by AI, HPC, industrial, and A&D demand, now the key growth engine.
• License and royalty revenue (Q2 2026 revenue $15M): Supportive to margin, but accounting timing matters, with guidance for $5M in Q3 and $10M per quarter for the following four quarters.
• Distributor channel (Not disclosed): Shipments rose 38.8% year over year, indicating broader demand strength outside a single hyperscaler program.
• Geography (Not disclosed): No geographic breakout was provided in the supplied data, so the read has to rely on end-market commentary rather than regional concentration.

Capital Allocation

Capital allocation looks conservative to a fault. Reported FCF, capex, buybacks, and dividends were all $0.0B in the supplied FY2025 data, while leverage stayed negligible at Debt/EBITDA 0.07, so the balance sheet has been preserved for internal investment rather than shareholder return. That is sensible given the need for a second fab, but it also means investors are underwriting future capacity spending without current cash return support.

Management Execution & Track Record

Execution has improved, but it has not been perfectly linear. On the 2024 Q3 call, management said, "Given the wide range of possible outcomes, we are unable to provide quarterly guidance until we are further along resolving uncertainties and capitalizing on opportunities," while book-to-bill was below 1 and one-year backlog was $150.6 million, down 2.1% sequentially. Since then, the company has moved from that uncertainty to guiding over $600 million of 2026 revenue, with backlog up 26% sequentially, book-to-bill above 1, and Q2 2026 revenue of $143.4 million, up 26.9% sequentially. The Gen 5 timing was slower than the 2024 call implied, because initial shipments and production ramps appear to have taken longer to translate into broad financial impact, but management has generally regained credibility through results, beating EPS in 7 of the last 8 reported quarters, including beats of +355.0%, +165.8%, and +59.5%.

Positioning & Flows

Ownership is relatively concentrated, with the top 3 institutions holding 42.1% and insiders owning 18.8%, which can amplify moves when the narrative changes. Short interest is only 5.70%, or 1,781,190 shares, with 2.1 days-to-cover, so there is some squeeze fuel but not enough to anchor a durable thesis by itself. Options positioning is supportive near term, with a positive GEX regime and zero-gamma at $239.58, below spot, which helps explain why upside moves can persist once the stock trades above that level.

Bull Case

• Advanced products revenue rose 45% sequentially to $94.2 million in Q2 2026, a direct sign that AI, HPC, industrial, and A&D programs are moving into a stronger phase.
• Backlog rose 26% sequentially and book-to-bill stayed above 1, supporting management's statement that Q3 revenue should increase by nearly 10%.
• Balance-sheet risk is minimal, with Debt/Equity 0.01, Debt/EBITDA 0.07, and a 13.25 current ratio, which gives Vicor flexibility to fund capacity additions.
• CHIPS Act tax credits added $14.3 million cash in July, with more expected, partially offsetting fab build and reconfiguration costs.

Bear Case

• Valuation is the core problem: 83.71x P/E, 25.88x P/S, and 14.7x P/B for a company that produced only 5.1% operating margin in FY2025.
• Near-term revenue quality is flattered by licensing, with $15 million recognized in Q2, stepping down to $5 million in Q3 before $10 million per quarter thereafter, which can create noisy comparisons.
• Management said the first fab is approaching capacity utilization, and the second fab is required to reach the longer-term $2.5 billion target, so supply could become the bottleneck before demand does.
• The stock setup is crowded after a 45.86% 1-week move and 29.23% 1-month move, with shares still 28.6% above the 200-day average despite being 29.9% below the 52-week high.

Valuation & Price Target

Engine price target $191.8 (-28.5% vs current), Low confidence.

• P/E Multiple: $111.42 (24% weight)
• PEG (growth-adjusted): $284.23 (20% weight)
• P/S Multiple: $25.18 (4% weight)
• Quality-adjusted: $262.76 (20% weight)
• DCF: $12.43 (4% weight)

The rating stays aligned with the quant baseline at SELL, though for a narrower reason than the model alone implies. The business trajectory is stronger than a simple trailing screen suggests, with guidance for over $600 million of 2026 revenue, 58% Q2 gross margin, and very low balance-sheet risk, so this is not a broken company call. The issue is price: at $268.34, investors are paying 83.71x earnings and 25.88x sales despite peer P/E averaging 29.7x across 10 peers, and the engine correctly flags that peer dispersion is wide at 6.0x, which lowers confidence in any exact target. Sell-side consensus is a Strong Buy from only 3 firms, which is too small a sample to outweigh valuation and execution timing risk.

Risk Assessment

Risk score 43/100 (Moderate). The biggest risk to a bearish stance is that AI power programs convert faster than expected, because management is already guiding to over $600 million of 2026 revenue and second-generation VPD production ramps are targeted for late Q3 to Q4 2027.

The Bottom Line

Rated SELL, Low conviction. Vicor is executing better, AI exposure is real, and the balance sheet is strong, but the stock still asks investors to pay too much too early. The base case remains the engine target of $191.8, because even strong 2026 growth does not fully justify 83.71x earnings and 25.88x sales. A more favorable stance would require either a materially lower entry price or clearer evidence that hyperscaler VPD programs and second-fab capacity can drive sustained earnings power well beyond 2026. Until then, the business deserves respect, but the stock does not.